<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="2308">
  <stage>Registered</stage>
  <submitdate>27/03/2009</submitdate>
  <approvaldate>27/03/2009</approvaldate>
  <nctid>NCT00872521</nctid>
  <trial_identification>
    <studytitle>A Study of Efficacy of Treatment With Bortezomib (in Combination With Doxorubicin and Dexamethasone) in Previously Untreated Patients With Multiple Myeloma</studytitle>
    <scientifictitle>A Phase II Trial of Bortezomib, Doxorubicin and Dexamethasone (PAD) Induction Therapy in Patients With Untreated Multiple Myeloma (MM), Stratified for Markers of Bortezomib Resistance</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>26866138MMY2059</secondaryid>
    <secondaryid>CR015640</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Multiple Myeloma</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Other cancer types</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - PAD induction

Experimental: bortezomib; doxorubicin; dexamethasone - PAD induction Open Label Treatment: Four 21-day Treatment Cycles Bortezomib 1.3 mg/m2 i.v. (D1 4 8 &amp; 11) Doxorubicin 20 mg/m2 i.v. (D1 &amp; 4) Dexamethasone 20 mg p.o. (D1 2 4 5 8 9 11 &amp; 12)


Treatment: drugs: PAD induction
Open Label Treatment:
Four 21-day Treatment Cycles Bortezomib 1.3 mg/m2 i.v. (D1, 4, 8 &amp; 11), Doxorubicin 20 mg/m2 i.v. (D1 &amp; 4), Dexamethasone 20 mg p.o. (D1, 2, 4, 5, 8 , 9, 11 &amp; 12)

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Overall Response Rate (ORR): Number of Participants Who Are Responders (Had Stringent Complete Response [sCR], CR, Very Good Partial Response [VGPR] or Partial Response [PR]) After 4 Cycles of Bortezomib, Doxorubicin and Dexamethasone (PAD) Induction - International Myeloma Working Group (IMWG) criteria - CR: negative immunofixation on the serum and urine, no soft tissue plasmacytomas and &lt;5% plasma cells in the bone marrow; sCR: CR+normal free light chain ratio, no clonal cells in bone marrow by immunohistochemistry or immunofluorescence; VGPR: serum and urine M-protein detected by immunofixation but not electrophoresis, &gt;90% in serum M-protein+urine, M-protein level &lt;100 mg/24hour; PR: =50% decrease of serum and M-protein, 24 hour urinary M-protein decrease by =90% or &lt;200 mg/24hour</outcome>
      <timepoint>84 days</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Disease Response After 4 Cycles of Bortezomib, Doxorubicin and Dexamethasone (PAD) Induction - Number of participants who achieved stringent complete response (sCR), complete response (CR), very good partial response (VGPR), partial response (PR) and stable disease (SD).</outcome>
      <timepoint>84 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Overall Response Rate (ORR) to Bortezomib, Doxorubicin and Dexamethasone (PAD) Induction 3-months Following Autologous Stem Cell Transplant (ASCT). - Responders are the number of participants who achieved stringent complete response (sCR)/ complete response (CR), very good partial response (VGPR) or partial response (PR) following PAD induction.</outcome>
      <timepoint>3-months following ASCT</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Disease Response 3-months After Autologous Stem Cell Transplant (ASCT) - Number of participants who achieved stringent complete response (sCR), complete response (CR), very good partial response (VGPR), partial response (PR), stable disease (SD) and relapse as per IMWG criteria.</outcome>
      <timepoint>3-months after ASCT</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Event Free Survival (EFS) - Percentage of participants who did not have any of the following events: Death, Disease progression, Relapse, Cardiovascular accidents, Deep vein thrombosis, Pulmonary embolism, Fracture, Acute renal failure, Nervous system disorders 2 years after Day 1 Cycle 1 of bortezomib, doxorubicin and dexamethasone (PAD).</outcome>
      <timepoint>2 years after Day 1 Cycle 1 of PAD</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Overall Survival - Percentage of participants who had no event of death 2 years after Day 1 Cycle 1 of bortezomib, doxorubicin and dexamethasone (PAD).</outcome>
      <timepoint>2 years after Day 1 Cycle 1 of PAD</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Assessment of Quality of Life (AQoL) Scores - The AQoL is a multi-attribute utility health-related quality of life (HRQoL) instrument. It combines the 4 dimensions of independent living, relationships, senses and mental health into a single utility score. The AQoL instrument scores between 1 (best HRQoL) and -0.04 (worst possible HRQoL).</outcome>
      <timepoint>Up to 2 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Overall Response Rate (ORR) Stratified by Protein Expression (p53) - Number of participants who are responders and nonresponders after 4 cycles of bortezomib, doxorubicin and dexamethasone (PAD) induction stratified by protein expression (p53).</outcome>
      <timepoint>84 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Overall Response Rate (ORR) Stratified by Protein Expression (Cyclin D1). - Number of participants who are responders and nonresponders after 4 cycles of bortezomib, doxorubicin and dexamethasone (PAD) induction stratified by protein expression (Cyclin D1).</outcome>
      <timepoint>84 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Overall Response Rate (ORR) Stratified by Protein Expression (Bcl-2) - Number of participants who are responders and nonresponders after 4 cycles of bortezomib, doxorubicin and dexamethasone (PAD) induction stratified by protein expression (bcl-2)</outcome>
      <timepoint>84 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Overall Response Rate (ORR) Stratified by Protein Expression (FGFR3) - Number of participants who are responders and nonresponders after 4 cycles of bortezomib, doxorubicin and dexamethasone (PAD) induction stratified by protein expression (FGFR3)</outcome>
      <timepoint>84 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Overall Survival (OS) Stratified by Protein Expression (p53). - Percentage of participants who had no event of death 2 years after Day 1 Cycle 1 of bortezomib, doxorubicin and dexamethasone (PAD) stratified by protein expression (p53).</outcome>
      <timepoint>2 years after Day 1 Cycle 1 of PAD</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Overall Survival (OS) Stratified by Protein Expression (Cyclin D1) - Percentage of participants who had no event of death 2 years after Day 1 Cycle 1 of bortezomib, doxorubicin and dexamethasone (PAD) stratified by protein expression (Cyclin D1).</outcome>
      <timepoint>2 years after Day 1 Cycle 1 of PAD</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Overall Survival (OS) Stratified by Protein Expression (Bcl-2) - Percentage of participants who had no event of death 2 years after Day 1 Cycle 1 of bortezomib, doxorubicin and dexamethasone (PAD) stratified by protein expression (bcl-2).</outcome>
      <timepoint>2 years after Day 1 Cycle 1 of PAD</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Overall Survival (OS) Stratified by Protein Expression (FGFR3) - Percentage of participants who had no event of death 2 years after Day 1 Cycle 1 of bortezomib, doxorubicin and dexamethasone (PAD) stratified by protein expression (FGFR3).</outcome>
      <timepoint>2 years after Day 1 Cycle 1 of PAD</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Previously diagnosed with multiple myeloma

          -  eligible for autologous stem cell transplantation

          -  meets pre-treatment lab criteria (as defined within protocol).</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Previously received treatment for multiple myeloma (including prior therapy with
             radiation or pulsed dexamethasone), except localised radiation to a solitary lesion or
             plasmacytomas or 4 days of corticosteroid therapy

          -  have a current diagnosis of smoldering multiple myeloma, monoclonal gammopathy of
             undetermined significance (MGUS), or Waldenstr√∂m Macroglobulinemia

          -  have a history of any other malignancy within 5 years before enrolment

          -  have other significant comorbidities.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/01/2009</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>107</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/11/2011</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital> - Adelaide</hospital>
    <hospital> - Box Hill</hospital>
    <hospital> - Brisbane</hospital>
    <hospital> - Camperdown</hospital>
    <hospital> - Geelong</hospital>
    <hospital> - Gosford</hospital>
    <hospital> - Greenslopes</hospital>
    <hospital> - Malvern</hospital>
    <hospital> - Melbourne</hospital>
    <hospital> - Parkville</hospital>
    <hospital> - Perth</hospital>
    <hospital> - Sydney</hospital>
    <hospital> - Westmead</hospital>
    <hospital> - Woden</hospital>
    <hospital> - Wollongong</hospital>
    <hospital> - Woolloongabba N/A</hospital>
    <postcode> - Adelaide</postcode>
    <postcode> - Box Hill</postcode>
    <postcode> - Brisbane</postcode>
    <postcode> - Camperdown</postcode>
    <postcode> - Geelong</postcode>
    <postcode> - Gosford</postcode>
    <postcode> - Greenslopes</postcode>
    <postcode> - Malvern</postcode>
    <postcode> - Melbourne</postcode>
    <postcode> - Parkville</postcode>
    <postcode> - Perth</postcode>
    <postcode> - Sydney</postcode>
    <postcode> - Westmead</postcode>
    <postcode> - Woden</postcode>
    <postcode> - Wollongong</postcode>
    <postcode> - Woolloongabba N/A</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Janssen-Cilag Pty Ltd</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to determine efficacy of treatment with bortezomib (in
      combination with doxorubicin and dexamethasone) in previously untreated patients with
      Multiple Myeloma.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00872521</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Janssen-Cilag Pty Ltd Clinical Trial</name>
      <address>Janssen-Cilag Pty Ltd</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>